Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.2174/1381612826666200713174140

http://scihub22266oqcxt.onion/10.2174/1381612826666200713174140
suck pdf from google scholar
32660401!ä!32660401

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32660401&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi


Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32660401      Curr+Pharm+Des 2020 ; 26 (41): 5224-5240
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy #MMPMID32660401
  • Rahman MH; Akter R; Behl T; Chowdhury MAR; Mohammed M; Bulbul IJ; Elshenawy SE; Kamal MA
  • Curr Pharm Des 2020[]; 26 (41): 5224-5240 PMID32660401show ga
  • The latest SARS COV2 coronavirus contributes to a pandemic of millions of COVID-19. As there is no defensive immunity in humans and a virus can overcome inborn immune reaction, it can propagate unhindered, mostly in tissues contaminated. No unique therapies for COVID-19 contaminated patients are available at this time. The insights learned from previous respiratory viral infection control have given guidance into COVID- 19 therapy. Several complementary treatments have been tentatively introduced in hospital environments such as immune-modulators, antiviral, convalescent plasma transfusions and natural products. In COVID-19 patients, some of these therapies have provided substantial curative benefits. Moreover, numerous studies and clinical trials are being carried out in order to determine the efficacy of current pharmaceutical and natural products to establish possible therapeutic strategies for producing novel COVID-19 medicines. We summarized and defined the modes of mechanism, protection and efficacy on the existing therapeutic strategies for diseases linked to COVID-19 infection.
  • |*COVID-19 Drug Treatment[MESH]
  • |*COVID-19/therapy[MESH]
  • |*Pharmaceutical Preparations[MESH]
  • |COVID-19 Serotherapy[MESH]
  • |Disease Outbreaks[MESH]
  • |Humans[MESH]
  • |Immunization, Passive[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box